- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02691234
Safety and Efficacy of Low Intensity Shockwave Therapy in Treating Diabetic Foot Ulcers
Low intensity shockwaves for treating diabetic foot ulcers (DFUs) have been in evaluation for the past 5 years. Many researchers showed the effectiveness of Low intensity shockwaves of in accelerating the healing rate of non-ischemic chronic DFUs. Wang et al. showed, the use of Low intensity shockwaves on DFUs, significantly improved topical blood flow perfusion rate, increased cell proliferation and cell activity and decreased cell apoptosis.
The present study deals with the effect of low intensity shockwaves on DFUs. Shockwave treatment will be done together with the standard conventional treatment for DFUs, compared to a control group who will receive the same conventional standard of care.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
- Fase 1
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Chronic non-healing diabetic foot ulcers for more than 2 months.
- Age 18-80 years
- Ankle Brachial Index (ABI) ≥0.6
- Diabetic Foot Ulcer with the long diameter of ≤7cm and a short diameter of ≥1cm
- The target ulcer is up to Wagner's grade 3
- Albumin level ≥25g/L
- Hemoglobin level ≥90g/L
- Estimated Glomerular Filtration Rate (eGFR) ≥30ml/min/1.73m2
- The patient agrees to comply with study protocol requirements, including the shockwave procedure, self-care of the ulcer (dressings, orthotics etc.) and all follow-up visit requirements
Exclusion Criteria:
- Pregnancy or lactation
- ABI <0.6
- The long diameter of the target ulcer is >7cm and the short diameter is <1cm
- The target ulcer is of Wagner's grade 4 or above
- Severe Hypoalbuminemia <25g/L
- Severe anemia, Hemoglobin level <90g/L
- eGFR <30ml/min/1.73m2
- Patients suffering from acute Charcot foot
- Severe edema of the treated limb
- Patient with present malignancy or past malignancy in the treated area
- Systemic chemotherapy/ radiation treatment within the last 6 months
- Deep vein thrombosis within the last 6 months
Any other experimental treatment or participation in other studies
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Extracorporeal Shockwave Therapy and debridement
The treatment will be performed as an outpatient care procedure with no anesthesia.
Patients will undergo wound debridement and cleansing before each treatment.
The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
|
|
|
Aktiv komparator: debridement and cleansing.
The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia.
Patients will undergo wound debridement and cleansing.
The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
To assess initial closure rate of the wound 4 weeks after the last treatment session, as compared to the control group receiving conventional standard of care.
Tidsramme: four weeks
|
four weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 0592-HMO-CTIL
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .